print_label | resize_label

ATAC 10- years data

After 10 years of follow-up in the ATAC trial, ARIMIDEX (anastrozole 1 mg tablets) is proven to deliver:
1. Demonstrated superior efficacy in disease-free survival (DFS), time to recurrence (TTR) and time to distant recurrence (TTDR) compared to tamoxifen
2. Early and long-term benefits sustained beyond treatment completion
View the ATAC 10-years results

Prescribing information

ARIMIDEX approved dose: 1 mg orally daily—supplied as white, round, biconvex tablet

Mechanism of action

ARIMIDEX—a highly selective, potent inhibitor of the aromatase enzyme Discover how ARIMIDEX works

Indication & efficacy

Indications and efficacy data

Reporting Adverse Events or Side Effects

AstraZeneca monitors the safety of our products by collecting, evaluating and reporting adverse events/side effects from a variety of sources. This is a critical component in the development of the prescribing information that provides healthcare professionals with the benefit/risk information they need to make appropriate prescribing decisions.

Countries worldwide may have specific processes in place to handle reports of adverse events. Please refer to the manufacturer contact information contained in the prescribing information to report any adverse events/side effects experienced by patients while taking an AstraZeneca prescription drug.